- About us
- About Vaccines
- Media centre
- EU initiatives
Europe is at the heart of global vaccine research and production. Most of the activities of the major innovative Vaccines Europe members research based-companies are based in the region.
Europe is a long-standing leader in vaccines. Maintaining this position and ensuring vaccine availability in times of increased demand and supply constraints can only be achieved by a committed industry, operating in a stable environment, able to produce vaccines of the highest quality and to innovate to meet future vaccine needs.
Shortages of medicines, including vaccines, are of increasing concern in the EU and globally. The causes are multiple. Finding solutions requires a concerted effort by all key stakeholders. Vaccines Europe is contributing to finding such solutions.
We describe the potential labelling/packaging improvements that could facilitate vaccine supply in our position paper accessible here.
Vaccination is one of the most cost-effective public health interventions ever implemented, significantly decreasing the worldwide incidence of numerous deadly diseases and associated mortality. To ensure the continuous and optimal protection of all citizens against infectious vaccine-preventable diseases, taking into consideration the ageing population, better access to immunisation should be ensured and provided throughout Europe. Expanding convenient access to vaccine administration should go together as a shared responsibility to vaccinate with all other Health Care Providers, HCPs (Doctors/GPs, nurses, midwives, pharmacists etc).
Find the VE paper on Improving Access and Convenience to Vaccination here.
The Early Career Research Prize in Vaccinology R&D is awarded by the International Union of Immunological Societies (IUIS) with the contribution of Vaccines Europe. The objective is to promote and foster a younger generation of scientists in the early stages of their career.
The prize rewards significant achievements in Vaccine R&D, including the discovery of new vaccine antigens, new vaccines design, understanding the basics of the immune response, new technologies that will improve the future of vaccines and vaccination and that are supported by proof-of-concept data (preclinical and clinical).
The Innovative Medicines Initiative (IMI) is celebrating its 10th anniversary with a high-level event. Organised jointly by IMI together with the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA), the event will take place at the European Commission’s Charlemagne Building in Brussels, Belgium on Wednesday 27 June 2018 from 13:00 to 18:00.